Hell, I can issue a competent shareholder update right now that will pass muster anywhere:
BIEL
Primary Product — ActiPatch
USPTO Patents - check
Up to date - check
FDA - partially OTC cleared foot and knee - check
FDA - working with company on back clearance - check
Trial supporting back clearance - finished - check
FDA asked for back data pre-submission meet - check
FDA relationship quality - fine
Signed deals with large U.S. distributors - check, do DD
Ongoing discussions with large U.S. retailers - check, do DD
ActiPatch OTC cleared 50+ countries - check
UK NHS Tariff approved for reimbursement - check
NHS support - trial data, efficacy, safety, price
NHS motives - public safety, efficacy, savings £100’s millions annually
Launch - Publicly announced April 1, 2018 Post-launch ramp-up, 90 days
NHS coverage - 100% insured patients with Rx
Estimated price on NHS Rx launch - $ .009 to $ .02
Estimated price on FDA OTC Back clearance - $ .04 to $ .06
Estimated price on FDA OTC General clearance - $ .075 to $ .09
Estimated price on U.S. retail (CVS, Walgreens) launch - $ .11 to $ .15
Is most of this factual? You bet
Is some of it speculative? You bet
p.s. ActiPatch is the only miniaturized, USPTO patented, drug-free, side-effect free, safe and efficacious (FDA says so), partially FDA OTC cleared, pain management device in the world and it works well. Fact
